3 active not recruiting, 1 completed. 4 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 3, Completed 1 |
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
Follow Klus Pharma Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003) SKB264, Pembrolizumab, Carboplatin - Non-small Cell Lung Cancer | Phase 2 | Active not recruiting | Klus Pharma Inc. | 356 | 2023-04-19 | 2026-01-27 |
| SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors SKB264, Pembrolizumab - Solid Tumor | Phase 2 | Active not recruiting | Klus Pharma Inc. | 240 | 2023-01-17 | 2025-10-14 |
| Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) SKB264 - Epithelial Ovarian Cancer, Gastric Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | Klus Pharma Inc. | 1410 | 2020-02-28 | 2026-10-09 |
| Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene A166 - HER2-positive Breast Cancer, HER2 Gene Mutation | Phase 1 / Phase 2 | Completed | Klus Pharma Inc. | 49 | 2018-07-16 | 2023-08-03 |
Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Uterine Cervical Neoplasms (2) · Bile Duct Neoplasms (1) · Carcinoma, Mucoepidermoid (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Cholangiocarcinoma (1) · Colonic Neoplasms (1) · Endometrial Neoplasms (1) · Head and Neck Neoplasms (1) · Laryngeal Neoplasms (1) · Lip Neoplasms (1) · Liver Neoplasms (1)
pembrolizumab (2) · Carboplatin (1) · Injections (1) · osimertinib (1)
China (3) · United States (3) · Canada (2) · South Korea (2) · Turkey (Türkiye) (2) · Australia (1) · Belgium (1) · Chile (1) · Georgia (1) · Poland (1) · Romania (1) · Spain (1)
Jordi Rodon Ahnert, MD, PhD (2)
2023 (1)